Swiss National Bank’s OptimizeRx OPRX Stock Holding History

Swiss National Bank’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-39,200	Closed	-$659K	–	2663
2022 Q4	$659K	Buy	39,200 +1,400	+4%	+$24.2K	﹤0.01%	2506
2022 Q3	$560K	Hold	37,800	–	–	﹤0.01%	2531
2022 Q2	$1.03M	Hold	37,800	–	–	﹤0.01%	2344
2022 Q1	$1.43M	Buy	37,800 +2,900	+8%	+$128K	﹤0.01%	2225
2021 Q4	$2.17M	Buy	34,900 +600	+2%	+$45.5K	﹤0.01%	2002
2021 Q3	$2.93M	Buy	34,300 +1,500	+5%	+$94.1K	﹤0.01%	1800
2021 Q2	$2.03M	Buy	+32,800	New	+$1.67M	﹤0.01%	2081

Other funds holding OPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Swiss National Bank's OPRX Position: Q1 2023 in Review

Swiss National Bank sold out of OptimizeRx (OPRX) in Q1 2023, closing a stake of 39,200 shares — an estimated $659K sold.

Swiss National Bank first reported a position in OPRX in Q2 2021 and held it in 7 quarters. The position peaked at $2.93M in Q3 2021. 110 funds tracked by Wall St. Rank hold OPRX as of Q1 2023.

Swiss National Bank reported no remaining OptimizeRx position as of Q1 2023 after selling out during the quarter.
Swiss National Bank sold 39,200 OptimizeRx shares in Q1 2023, an estimated $659K.
Swiss National Bank first reported a position in OptimizeRx in Q2 2021 and held it in 7 quarters.
Swiss National Bank's OptimizeRx position peaked at $2.93M in Q3 2021.
110 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2023.

Based on Swiss National Bank's 13F filing for Q1 2023, filed 10 May 2023.